



Notice: Carelon Medical Benefits Management Genetic Testing Guidelines

Effective April 1, 2024

This notice applies to UniCare members in the Total Choice, PLUS, and Community Choice plans.

Effective April 1, 2024, UniCare will transition to the following Carelon Genetic Testing guidelines to perform medical necessity/clinical appropriateness reviews for requested genetic tests. Applicable CPT code lists are included in the guidelines (link provided below).

- Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing
- Cell-free DNA Testing for the Management of Cancer
- Chromosomal Microarray Analysis
- Genetic Testing for Inherited Conditions
- Hereditary Cancer Testing
- Pharmacogenomic Testing
- Polygenic Risk Scores
- Prenatal Testing using cell-free DNA
- Somatic Tumor Testing
- Whole Exome Sequencing and Whole Genome Sequencing

Prior authorization requirements remain the same. The requested services received on or after April 1, 2024 will be reviewed with the new clinical criteria.

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management using the Carelon Medical Benefits Management **ProviderPortal**SM at providerportal.com. **ProviderPortal** is available 24 hours a day, seven days a week, processing requests in real-time. It is the fastest and most convenient way to request authorization.

For questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com.

In addition, you may access and download a copy of the current and upcoming guidelines at <https://guidelines.carelonmedicalbenefitsmanagement.com/current-genetic-testing-guidelines/>.